Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties

OMEROS CORP

Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.
Royalties: 50% of U.S. net sales until earlier of Jan 1, 2025 or milestone paid, then 30%; 15% on ex-U.S. net sales.
Transaction valued in excess of $1 billion including royalties; Omeros retains $34M accounts receivable.
Omeros to focus on complement franchise of MASP-2 and MASP-3 inhibitors.
Closing expected on or before Dec 31, 2021, subject to HSR waiting period expiration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.